Системная фармакокинетика и биодоступность L-глутамината 2-диэтиламино-2’,6’-диметилфенилацетамида

Р. М. Термулаева, Д. С. Блинов(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Е. В. Семелева, Д. Е. Тимошкин, Е. В. Блинова(Physical Sciences (United States)), А. С. Пирожков, С. Я. Скачилова, К. Д. Блинов, А. А. Дмитриев, Н. Д. Бунятян, М. А. Р. Фарахманд
Химико-фармацевтический журнал
September 3, 2025
10.30906/0023-1134-2025-59-8-59-64
Cited by 0

Related Papers

Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
|Cells|2019|19
Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
|International Journal of Molecular Sciences|2022|16
Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice
|Journal of Advanced Pharmaceutical Technology amp Research|2018|14
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
|Life|2020|13
Anticancer signal transduction pathways of selenium nanoparticles in mouse colorectal cancer model
|Biochemical and Biophysical Research Communications|2025|12